About Revium Rx

Erez joined Revium in 2023, bringing over 15 years of experience in pharma and biotech R&D.

He previously served as Head of Early-Stage CMC at Clexio Biosciences, where he was responsible for formulation development and phase 1-2 regulatory submissions. Prior to that, Erez led the Innovative R&D Pharma Lab at Teva Pharmaceuticals. He also led CMC activities at Lipocure Ltd. and contributed to the FDA submission and approval of a liposomal drug product (ANDA). Erez holds a Ph.D. in pharmaceutical sciences and completed postdoctoral training at Northeastern University (Boston, MA). Erez has authored over 40 peer-reviewed papers and contributed to five patent applications.

Yoram Drucker is a serial entrepreneur with over 25 years of experience in business development, fundraising, and executive roles in the biotechnology sector.

He co-founded and contributed to the development of three publicly-traded biotech companies, including Brainstorm (NASDAQ:BCLI), where he served as COO and CEO, and Pluri Biotech (NASDAQ: PLUR; TLV:PLUR).

Inna brings over 20 years of experience in venture financing, portfolio management and M&As.

Prior to joining Revium, Inna co-founded SPAS™, an innovative cardiovascular solution which is now being adopted by several leading clinics in the US. Inna served as a managing partner at a $760 million sovereign fund focused on healthcare innovation where she managed a portfolio of medical devices and pharmaceutical companies with a combined exit value of over $1.5 billion. Inna has served on the boards of multiple US and Israeli startup companies.

Arie brings to Revium 14 years of experience in accounting, audit and financial management of hi-tech and biotechnology companies.

Since 2018, he serves as Head of IPO & M&A Department at a one of the leading accounting firms of Israel. Prior to that, Mr. Gordashnikov served as an Audit Manager at Ernst & Young Israel. Mr. Arie is licensed CPA since 2012 and has extensive experience in RCC and PCAOB reporting.

Ohad is a seasoned pharmaceutical executive with over two decades of experience in drug development, CMC, and regulatory affairs.

He has led formulation and regulatory strategy efforts across a range of therapeutic areas and development stages. Prior to joining ReviumRx, Ohad held senior leadership roles at Insightec (TASE: EMTC), Rafa Laboratories, Tiltan Pharma, and BioLineRx (Nasdaq: BLRX), where he led the development of both innovative and generic drug products, including sterile injectables, semi-solids, and oral formulations.

Ohad holds a Ph.D. in Pharmaceutics, an MBA, and a B.Pharm from the Hebrew University of Jerusalem.

Amir Avraham is a senior finance executive with over 20 years of leadership experience across high-tech and biotech sectors, specializing in financial strategy, M&A, and international operations.

As CFO and General Manager of OCON Therapeutics,, he led strategic planning and capital raises totaling over $15 million while managing legal, financial, and global activities. Previously, he was CFO at Secure Islands Technologies, a cybersecurity firm acquired by Microsoft. There, he led financial operations across the US, UK, and Switzerland, managed investor relations, and was instrumental in both a $20 million fundraising round and the Microsoft acquisition process. Earlier in his career, he held leadership roles at Van Leer Ventures and Deloitte. Mr. Avraham is a licensed CPA and holds an MBA in Finance from the Hebrew University of Jerusalem.

Allon is a renowned leader in infectious diseases, clinical microbiology, and hospital epidemiology.

He served as chairman of the Department of Clinical Microbiology and Infectious Diseases at Hadassah University Medical Center in Jerusalem and president of the Israeli Society of Infectious Diseases, contributing significantly to public health and medical research. His expertise in infectious disease management, antimicrobial resistance, and hospital epidemiology has influenced national infection control policies in several countries across Africa and Asia, improving patient safety and healthcare standards. As a professor of clinical microbiology, he remains dedicated to mentoring future medical professionals and advancing global infectious disease research.

Itzhak has co-authored 143 peer-reviewed papers, with 8661 citations and an H-index of 43.

His cancer research career includes postdoctoral work at UC Berkeley and founding one of the first precision medicine services at Peter MacCallum Cancer Centre. He cofounded the NICTA life science program in Australia and Israel’s fifth medical school, playing a key role in biomedical research and COVID-19 pandemic control strategies.

Yechezkel is a world-renowned professor of biochemistry at the Hebrew University of Jerusalem and the head of the Liposome and Membrane Research Lab.

He has co-authored more than 440 publications with more than 47,700 citations and holds more than 55 patents, more than half of which have been licensed. He is one of the key inventors of Doxil®, the first FDA-approved nano-drug for cancer treatment. He has cofounded 6 startups and is currently developing 6 additional liposomal drugs for various medical applications. His work bridges biology, nanotechnology, and medicine. Among his many awards, he received the 2020 EMET Prize in Nanotechnology, and he is ranked among the top 2500 scientists globally.